click here<\/a>.<\/p>\nAbout us<\/h2>\n
Founded in 2007, Vantage BioTrials is a privately-held Contract Research Organization (CRO) that provides Phase I-IV clinical trial management services and implements Risk-Based Management through the use of Quality by Design (QbD) methodologies, all delivered to international pharmaceutical, biotechnology, generic pharmaceutical and medical device companies.<\/p>","protected":false},"excerpt":{"rendered":"
President of Vantage BioTrials Interviewed by Pharmaboardroom on the State of Clinical Trials in Canada Vantage BioTrials\u2019 President, Vatche Bartekian, was recently interviewed by Pharmaboardroom on ways that the company focuses on operational excellence with a lean and holistic approach to each project and how they continually advocate for greater visibility for\u00a0Canada\u00a0on the international stage and an increase in collaboration within the pharmaceutical industry and regulatory bodies. \u201cWhat we can observe in\u00a0Canada\u00a0is a very diverse CRO landscape, in which each player has found its own specialty.\u201d In this in depth interview with Bartekian, you will discover how Vantage BioTrials differentiates itself with its business model from other CROs, some of the the challenges facing CROs as well as advantages in conducting clinical trials in Canada, the company\u2019s approach to team management and leadership and the evolution of leadership roles within the Canadian life sciences ecosystem. To read more about this compelling interview please\u00a0click here. About us Founded in 2007, Vantage BioTrials is a privately-held Contract Research Organization (CRO) that provides Phase I-IV clinical trial management services and implements Risk-Based Management through the use of Quality by Design (QbD) methodologies, all delivered to international pharmaceutical, biotechnology, generic pharmaceutical and medical device companies.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[20],"tags":[],"class_list":["post-1297","post","type-post","status-publish","format-standard","hentry","category-news-pressroom","cms-no-post-thumbnail"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/1297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/comments?post=1297"}],"version-history":[{"count":0,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/1297\/revisions"}],"wp:attachment":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/media?parent=1297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/categories?post=1297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/tags?post=1297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/vantagebiotrials.com\/wp-content\/uploads\/2018\/01\/Vatche_Headshot_1001276v5-570x570.jpg\")
Vantage BioTrials\u2019 President, Vatche Bartekian, was recently interviewed by Pharmaboardroom on ways that the company focuses on operational excellence with a lean and holistic approach to each project and how they continually advocate for greater visibility for\u00a0Canada\u00a0on the international stage and an increase in collaboration within the pharmaceutical industry and regulatory bodies.<\/p>\n